Clinical Trial Results:
            A Phase 2b Study of BMS-790052 in Combination with Peg-Interferon
Alfa-2a and Ribavirin in Treatment Naive Subjects with Chronic Hepatitis
C Genotype 1 and 4 Infection
Revised Protocol Number 03, incorporating amendments 03, 04 and 05
+ Pharmacogenetics Blood Sample Amendment Number 01 - Site Specific (version 1.0, dated 16-Apr-10)
    
|     Summary | |
|     EudraCT number | 2010-018295-24 | 
|     Trial protocol | SE DE FR IT DK | 
|     Global completion date | 
                                    29 Aug 2012
                             | 
|     Paediatric regulatory details | |
|     Is the trial part of an agreed EMA paediatric investigation plan? | 
                                        No
                                 | 
|     Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? | 
                                        No
                                 | 
|     Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? | 
                                        No
                                 | 
|     Results information | |
|     Results version number | v1(current) | 
|     This version publication date | 
                                    07 Dec 2016
                             | 
|     First version publication date | 
                                    07 Dec 2016
                             | 
|     Other versions | |
|     Summary report(s) | AI444-010_Synopsis | 
            Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to            Commission Guideline 2012/C 302/03
            for further information.    
 
				
